Elixirgen Therapeutics

A clinical-stage RNA therapeutics company focused on the discovery and development of innovative therapies, including cell and gene therapies.

[Elixirgen Therapeutics @ElixirgenTx]

Research in #TelomereBiologyDisorders requires continued scientific & clinical insight. Previously in @NEJMEvidence, our ZSCAN4 study showed sustained telomere elongation in blood cells. We’re advancing this work in a Phase 1/2 #ClinicalTrial. Read more: https://t.co/qeCVAUaxcr

[Labiotech.eu @Labiotech_eu]

We look at six biotechs in Maryland that have received funding over the past five years that are ready to take their technologies further into the clinic. https://t.co/dDHCcJDslw

[Elixirgen Therapeutics @ElixirgenTx]

This #DNADay26, we celebrate the discovery of DNA & the science driving innovation in health. Through understanding the biology of #TBDs, we have the potential to develop life-changing therapies for people living with TBDs.

Learn more: https://t.co/IhFTfbdOKi

[Elixirgen Therapeutics @ElixirgenTx]

At Elixirgen, we’re advancing a new approach for #TBDs. Our lead candidate is currently in a Ph1/2 trial for TBDs with bone marrow failure & has received FDA Rare Pediatric Disease, Regenerative Medicine Advanced Therapy and Orphan Drug designations: https://t.co/0MY1SRkC9R

[Elixirgen Therapeutics @ElixirgenTx]

#TBDs are often diagnosed in childhood, but are increasingly seen in adults with pulmonary fibrosis, liver disease, or bone marrow failure. While limited treatments exist, we’re advancing a therapy to meet unmet patient needs. More from @TeamTelomereInc: https://t.co/k8hQYySgoT

[Elixirgen Therapeutics @ElixirgenTx]

#DYK, #TelomereBiologyDisorders (#TBDs) are rare genetic conditions resulting in abnormally short telomeres, the protective caps of DNA? When too short, cells may not function properly, leading to serious complications like bone marrow failure. Learn more: https://t.co/IhFTfbdOKi

[Elixirgen Therapeutics @ElixirgenTx]

#DYK, 1 in 10 people in the US are affected by a rare disease, like #TelomereBiologyDisorders (TBDs)? On #RareDiseaseDay, we recognize those affected by #RareDiseases & express our commitment to advance our Phase 1/2 trial gene therapy for TBDs. More here: https://t.co/IhFTfbdOKi

[Elixirgen Therapeutics @ElixirgenTx]

Today we published encouraging early data from our Phase 1/2 #ClinicalTrial in @NEJMEvidence. The study demonstrates telomere elongation and increased ANC in two patients with #TelomereBiologyDisorders following EXG-34217 treatment. Read more here: https://t.co/jltZ6oircX

[Elixirgen Therapeutics @ElixirgenTx]

We’re happy to announce that the FDA has granted Orphan Drug Designation to our gene therapy for treatment of #Telomere Biology Disorders. More in the press release here: https://t.co/sDcyTpgSD7

[Elixirgen Therapeutics @ElixirgenTx]

We’re pleased to annouce that the FDA has granted Regenerative medicine Advanced Therapy (RMAT) Designation to our gene therapy for treatment of #Telomere Biology Disorders. More in the press release here: https://t.co/LcbmIACAHM

[Elixirgen Therapeutics @ElixirgenTx]

As we reflect on the year, we’re especially grateful for the incredible dedication and passion of our team at Elixirgen Therapeutics, our advisors, and the community that supports us. Together, we have the potential to make a lasting difference for patients.

[Elixirgen Therapeutics @ElixirgenTx]

#ICYMI this @BioProcessOL article highlights how we're pioneering a decentralized approach to manufacturing and delivery, offering potential logistical and efficacy benefits in our #CellTherapy. Read the article here: https://t.co/0nD4DyvfZD

[Elixirgen Therapeutics @ElixirgenTx]

🧬 November is #TBDMonth! We're developing a therapy to treat #TelomereBiologyDisorders, a #RareDisease characterized by shortened #telomeres. Join us in raising awareness & supporting innovative solutions for those affected. Learn more from @TeamTelomere: https://t.co/GoEOH3sqHA

[Elixirgen Therapeutics @ElixirgenTx]

#DYK that while #DuchenneMuscularDystrophy is a rare muscle disorder, it is one of the most frequent genetic conditions, affecting 1 in 3,500 male births worldwide? Learn how we're exploring the potential of our Bobcat mRNA™ in treatment for #DMD: https://t.co/IhFTfbdOKi

[Elixirgen Therapeutics @ElixirgenTx]

#RNA plays a crucial role in biology and is a powerful tool in modern medicine. At Elixirgen Therapeutics, we are reimagining the power of RNA to develop various technologies for the treatment of #RareDiseases. Learn more here: https://t.co/J1qxDvhq4l

[Elixirgen Therapeutics @ElixirgenTx]

Living with a #TelomereBiologyDisorder can deeply impact patients & families. As we work to develop a #CellTherapy for TBDs, we're proud to partner with @TeamTelomere & foster a strong patient community. Read some of their inspiring stories here: https://t.co/X5C2RrtR5F

[Elixirgen Therapeutics @ElixirgenTx]

We’re pleased to announce that the FDA has granted Rare Pediatric Disease Designation to our candidate in #TelomereBiologyDisorders. We look forward to continuing the advancement of our program to address the significant unmet need in TBD. More here: https://t.co/278trlKjzV

[Elixirgen Therapeutics @ElixirgenTx]

As we wrap up Muscular Dystrophy Awareness Month (MDAM), we reaffirm our commitment to combatting #DuchenneMuscularDystrophy (DMD) with our Bobcat mRNA™ to restore muscle function. Learn more: https://t.co/J1qxDvhq4l

[Elixirgen Therapeutics @ElixirgenTx]

We're attending the Clinical Trials in Rare Diseases Conference 2024! We’re committed to developing treatments for #RareDiseases & improving quality of life for patients affected by these conditions. More here: https://t.co/3zleC2vtkS

[Elixirgen Therapeutics @ElixirgenTx]

We're excited to participate in the RNA Leaders USA Congress this week! Hear from our Co-founder & CEO, Aki Ko, about how we're developing life-changing therapies for patients in need using our cutting-edge #RNA technology. Learn more: https://t.co/pZBtXV3kac